The aim of this work was to assess the use of a sustained-release formulation of somatuline, a l ong\ x=req-\ acting analogue of somatostatin, in the treatment of acromegaly. Fifteen patients with active acromegaly, as defined by random growth hormone (GH) levels greater than 10 mU/l, which fail to be suppressed to less than 5 mU/l following an oral glucose load, were studied. Somatuline was administered as an intramuscular injection in two regimens: eight patients were given a single injection of the sustained-release formulation and blood samples taken over the next month for the measurement of both basal levels of GH and the GH response to thyrotrophin-releasing hormone; and eight patients were given injections of the sustained-release formulation at 2-week intervals over a 6\ x=r eq-\ month period and basal plasma GH levels and the GH response to both an oral glucose load and to thyrotrophin-releasing hormone was assessed. Following a single intramulscular dose of the sustained-release preparation, random GH levels were reduced to below 10 mU/l in five patients and by greater than 50% of basal levels in the remainder. The insulin-like growth factor I (IGF-I) levels fell to within the normal range in three patients. In the long-term efficacy study, GH levels were reduced to < 10 mU/l in 7/8 patients. The IGF-I levels were normalized in four patients. Five Recently, an alternative to octreotide, somatuline, has become available. Circulating GH levels are reduced by somatuline administered either as an infusion in normal men or as a slow-release intramuscular depot in acromegalie patients (7, 8) . We have been using the long-acting sustained release preparation of somatuline in the management of acromegaly and report here the pharmacokinetics and its effects on the random and dynamic circulating levels of GH and IGF-I of the sustained-release formulation.
Recent advances in the diagnosis and management of acromegaly have allowed patients to be treated earlier, more effectively and with fewer side-effects. Previously, the diabetic and cardiovascular complications of acromegaly have resulted in a doubling of expected mortality (1) . This, and the considerable morbidity associated with acromegaly, has driven the search for a more effective management for those patients who are unsuitable for surgery, or who require treatment while waiting for radiotherapy to take effect. Bromocriptine controls 19% of these cases (2) , but the remainder are either unable to tolerate bromocriptine or resistant to it. For these patients the advent of the long-acting analogues of somatostatin has provided a viable alternative (3, 4) . At present the only available agent, octreotide has to be given either as a continuous infusion or in three divided doses subcutaneously (5, 6) .
The mode of administration of octreotide and its expense have been the limiting factors in its use. Recently, an alternative to octreotide, somatuline, has become available. Circulating GH levels are reduced by somatuline administered either as an infusion in normal men or as a slow-release intramuscular depot in acromegalie patients (7, 8) . We 
Efficacy of repeated injections of somatuline
The IGF-I (Fig. 2 a and b) and random GH levels (Fig.  2 c) and the GH response to TRH and to glucose were reduced in all cases. The IGF-I levels remained suppressed in 4/8 patients ( Fig. 2a and b) . Random GH levels were reduced to below 10mU/l in seven patients, but one patient (patient 5) showed no response to treatment. In two patients (patients 1 and 3), following a good initial response, GH levels rose towards the end of the study (Fig. 2c) (Fig. 2d ). There were no correlations between the circulating levels of somatuline and those of either IGF-I or GH.
Symptomatic relief
Two patients had marked symptomatic improvement, which included an improvement of their facial signs and reduction in the volume of hands and feet. The remainder, all with long-standing acromegaly, showed little objective change.
Side effects
Five patients had diarrhoea, two of mild (one occasion, for less than 48 h) and three of moderate severity (after each injection, for less than 48 h). Four had abdominal cramps. No patients withdrew from the study. One patient developed biliary sludge over the period of study. (14) .
The advantage of this long-acting analogue of somatuline lies in its availability as a sustained-release formulation, allowing a markedly reduced frequency of administration. The side-effects of octreotide and somatuline relate to their somatostatinergic activity, and the incidence of the side-effects seems to be similar with both agents (15) . In conclusion, we find that somatuline is an effective drug in the treatment of acromegaly, and that the sustained-release preparation represents a technical advance in the pharmacological treatment of the disease. Further studies are needed to ascertain the optimum dose and frequency of adminis¬ tration of this new formulation.
